Pfizer CEO backs out of EU COVID committee hearing
No Accountability for Pfizer as Bourla Ignores EU Covid Committee Hearings
Tag: Pfizer
New COVID Booster Approved From Final Study of Mice, Not Humans, But Using Only Animal Data Is a Needless Gamble
VERIFY: New COVID booster approved from final study of mice, not humans
According to documents on the CDC website, human tests of Moderna’s version of the new booster are still “ongoing.” Right now, there is only final evidence from “8-10 mice” per group.”
The FDA’s website shows for Pfizer the agency also relayed on the final study evidence from “8 mice.” But human trials are also ongoing. So far, the new boosters “showed a similar local reaction and systemic event profile.” That means side effects appear to be about the same including “mild to moderate injection site pain, fatigue, and muscle pain.”
…
“To advance the Omicron BA.4/BA.5 bivalent vaccine as rapidly as possible, regulators, including the FDA, WHO and EMA, have advised that our submissions be based on safety and immunogenicity data generated in adults with an Omicron BA.1 bivalent vaccine and supported by BA.4/BA.5 bivalent pre-clinical data and BA.4/BA.5 bivalent quality and manufacturing data. These packages follow a similar model to that provided to public health officials who evaluate seasonal flu vaccines each year. Moving forward, this approach may help address the pressing need for vaccines that provide a high level of protection against current and emerging variants of concern so that we can remain vigilant against this evolving virus. The FDA has authorized our Omicron BA.4/BA.5 bivalent vaccine based on clinical data generated in adults with an Omicron BA.1 bivalent vaccine, pre-clinical data with a BA.4/BA.5 bivalent vaccine and BA.4/BA.5 bivalent quality and manufacturing data. Pre-clinical data showed a booster dose of Pfizer and BioNTech’s Omicron BA.4/BA.5- bivalent vaccine generated a strong neutralizing antibody response against Omicron BA.1, BA.2 and BA.4/BA.5 variants, as well as the original wild-type strain. A clinical study investigating the safety, tolerability and immunogenicity of the Omicron BA.4/BA.5 bivalent vaccine in individuals 12 years of age and older is ongoing. Data will be shared with regulators when available. We are facing a virus with an exceptionally high mutation rate, which the nimble mRNA platform is well situated to address. Only the mRNA sequence requires updating to match emerging strains, and utilizing a bivalent vaccine aims to provide broader coverage against known and future COVID-19 variants of concern.”
Related:
Read More »Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults
Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults
The report’s authors found that Pfizer’s antiviral medication Paxlovid offered little to no benefit for younger adults. However, it did reduce the risk of hospitalization for high-risk seniors. Notably, supplementary material from the original study of Paxlovid in high-risk non-hospitalized adults with COVID-19 during the Delta wave had demonstrated benefits in those younger than 65, albeit the difference compared to the placebo was much less than in those 65 and older.
…
Among those over 65, there was a 73 percent decrease in the hospitalization rate and a 79 percent reduction in the risk of death. However, patients between the ages of 40 and 65 saw no benefit in taking the antiviral medication in either category, regardless of previous immunity status.
…
Another critical study from Hong Kong published in Lancet Infectious Diseases on the same day as the Israeli study but which went unmentioned in the press offered further evidence of Paxlovid’s limited therapeutic role. The authors reviewed their clinical experience with Paxlovid and Lagevrio, Merck’s antiviral pill, Molnupiravir, in hospitalized patients. They compared them to hospitalized patients who did not receive those medications during the horrific wave of infections that slammed into the semi-autonomous region in February and March.
…
The mortality risk reduction for Lagevrio was 52 percent, and for Paxlovid it was 66 percent. Those receiving antivirals had a lower risk of their disease progressing, but the drugs did not significantly impact their need for mechanical ventilation or ICU admission. The patients in the study averaged in age from mid-70s to early 80s.
…
Given the results of these studies, it bears mentioning that the Centers for Disease Control and Prevention (CDC) has recently estimated that approximately 95 percent of Americans aged 16 and older have some level of immunity against COVID-19.
Thai vaccine study
Pfizer Jab Fails It’s CEO, Albert Bourla
The jab that failed on all counts BUT one.
…
The top executive at Pfizer, a leading producer of COVID-19 vaccines, has tested positive for the virus and says he is experiencing very mild symptoms.
Chairman and CEO Albert Bourla said Monday that he started taking Pfizer´s Paxlovid pill treatment and is isolating while he recovers.
Pfizer Jab Fails It’s CEO, Albert Bourla
Waiting for the Paxlovid Rebound…
Biden experiences a Covid rebound after treatment with one course of Paxlovid
Biden experiences a Covid rebound after treatment with one course of Paxlovid
The president was not masked at public events he attended at the end of the week, which is in conflict with CDC guidance that says people should wear a mask for 10 days after a Covid infection.
White House press secretary Karine Jean-Pierre said during a briefing that the president was still in compliance with CDC guidelines because he was more than six feet apart from other people.
Biden tests positive for COVID-19, has ‘very mild symptoms’
By ZEKE MILLER and CHRIS MEGERIAN, Associated Press
WASHINGTON (AP) — President Joe Biden tested positive for COVID-19 on Thursday and is experiencing “very mild symptoms,” the White House said, as new variants of the highly contagious virus are challenging the nation’s efforts to get back to normal after two and a half years of pandemic disruptions.
Biden tests positive for COVID-19, has ‘very mild symptoms’
DOUBLE-BOOSTED Fauci’s Covid WORSENS After Paxlovid Rebound.
Related:
Fauci Says He Had Paxlovid Rebound, Worse Symptoms:
Fauci first tested positive after having a “scratchy throat,” he told the newspaper. After taking Paxlovid, he was “surprised and disappointed” to see he tested positive again, and he had symptoms such as a low fever, achiness, runny nose, and “mild cough.” He then called his doctor, who prescribed another 5-day course of Paxlovid, which Fauci said is relatively common among those who have a rebound.
…
Earlier this month, Pfizer, the maker of Paxlovid, announced that it would stop adding new people to a clinical trial of the drug among COVID-19 patients who have a low risk of hospitalization and death. The study failed to show that the drug reduced symptoms, hospitalizations, or deaths in a statistically significant way, Bloomberg reported.
COVID-19 Rebound After Paxlovid Treatment:
There is currently no evidence that additional treatment is needed with Paxlovid or other anti-SARS-CoV-2 therapies in cases where COVID-19 rebound is suspected.
Going against CDC guidance, huh?! Hypocrite!
Pfizer reportedly sponsored Miami yacht party for failed Colombian presidential contender Rodolfo Hernández
This article was originally published by Orinoco Tribune, June 18, 2022.
Editor’s note: Rodolfo Hernández, lauded in US mainstream media as an “anti-corruption” crusader, was defeated by left-wing politician Gustavo Petro in his bid for the presidency on June 19, 2022. Under the presidency of Ivan Duque, Colombia overpaid by as much as $375 million for Pfizer’s Covid-19 vaccine. According to secret contracts with Pfizer that were later leaked, Colombia was compelled by Pfizer to forfeit “immunity against precautionary seizure of any of [their state] assets.” A peer-reviewed May 2022 study by Jama Network Open found that “immunity against the omicron coronavirus variant fades rapidly after a second and third dose of Pfizer and BioNTech’s Covid-19 vaccine.”
Pfizer reportedly sponsored Miami yacht party for failed Colombian presidential contender Rodolfo Hernández
Why America Doesn’t Trust the CDC
Why America Doesn’t Trust the CDC
Most remarkably, it didn’t seem to matter to the CDC that 75.2 percent of children under age 11 already have natural immunity, according to a CDC study that concluded in February. Natural immunity is certainly much more prevalent today, given the ubiquity of the Omicron variant since February. CDC data from New York and California demonstrated that natural immunity was 2.8 times more effective in preventing hospitalization and 3.3 to 4.7 times more effective in preventing COVID infection compared to vaccination during the Delta wave. These findings are consistent with dozens of other clinical studies. Yet natural immunity has consistently and inexplicably been dismissed by the medical establishment.
…
Public health officials are expected to recommend COVID vaccines for children under 5 as soon as June 21st, despite the fact that the vast majority of children already have natural immunity. In a recent Kaiser survey, only 18 percent of parents said they were eager to vaccinate their child in that age group.
Ms. Cat’s Chronicles 
You must be logged in to post a comment.